Alexion Pharmaceuticals Inc. [NASDAQ: ALXN] gained 0.44% or 0.8 points to close at $184.20 with a heavy trading volume of 10828437 shares. The company report on June 11, 2021 that Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021.
– Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response -.
Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in patients with AL amyloidosis. The data, presented in two e-posters at the European Hematology Association (EHA) Congress 2021, strengthen the safety and tolerability profile of CAEL-101, further support the dose selection for the ongoing Phase 3 study, and suggest possible cardiac and renal response. An e-poster featuring the first data from a new arm of the study demonstrated that CAEL-101 administered in combination with cyclophosphamide-bortezomib-dexamethasone (CyBorD) plus daratumumab was generally safe and well-tolerated in the first four weeks of treatment. Data presented in a second e-poster showed longer-term evidence that CAEL-101 in combination with CyBorD was generally well-tolerated for a median treatment duration of 49 weeks, and exploratory clinical biomarker data suggesting possible cardiac disease improvements and renal response among patients with cardiac or renal impairment at baseline, respectively.
It opened the trading session at $183.24, the shares rose to $185.50 and dropped to $182.64, the range by which the price of stock traded the whole day. The daily chart for ALXN points out that the company has recorded 18.27% gains over the past six months. However, it is still -84.37% lower than its most recent low trading price.
If we look at the average trading volume of 2.12M shares, ALXN reached to a volume of 10828437 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Alexion Pharmaceuticals Inc. [ALXN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ALXN shares is $177.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ALXN stock is a recommendation set at 2.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Alexion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 05, 2021. While these analysts kept the previous recommendation, Credit Suisse raised their target price to Neutral. The new note on the price target was released on April 26, 2021, representing the official price target for Alexion Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Alexion Pharmaceuticals Inc. is set at 1.97, with the Price to Sales ratio for ALXN stock in the period of the last 12 months amounting to 6.49. The Price to Book ratio for the last quarter was 3.27, with the Price to Cash per share for the same quarter was set at 15.72. Price to Free Cash Flow for ALXN in the course of the last twelve months was 13.66 with Quick ratio for the last quarter at 4.00.
Trading performance analysis for ALXN stock
Alexion Pharmaceuticals Inc. [ALXN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.49. With this latest performance, ALXN shares gained by 2.80% in over the last four-week period, additionally plugging by 18.27% over the last 6 months – not to mention a rise of 69.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ALXN stock in for the last two-week period is set at 62.83, with the RSI for the last a single of trading hit 59.83, and the three-weeks RSI is set at 64.56 for Alexion Pharmaceuticals Inc. [ALXN]. The present Moving Average for the last 50 days of trading for this stock 177.59, while it was recorded at 184.54 for the last single week of trading, and 151.31 for the last 200 days.
Alexion Pharmaceuticals Inc. [ALXN]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Alexion Pharmaceuticals Inc. [ALXN] shares currently have an operating margin of +47.43 and a Gross Margin at +86.69. Alexion Pharmaceuticals Inc.’s Net Margin is presently recorded at +9.95.
Return on Total Capital for ALXN is now 20.17, given the latest momentum, and Return on Invested Capital for the company is 4.28. Return on Equity for this stock inclined to 5.26, with Return on Assets sitting at 3.39. When it comes to the capital structure of this company, Alexion Pharmaceuticals Inc. [ALXN] has a Total Debt to Total Equity ratio set at 24.38. Additionally, ALXN Total Debt to Total Capital is recorded at 19.60, with Total Debt to Total Assets ending up at 15.69. Long-Term Debt to Equity for the company is recorded at 22.86, with the Long-Term Debt to Total Capital now at 18.38.
Reflecting on the efficiency of the workforce at the company, Alexion Pharmaceuticals Inc. [ALXN] managed to generate an average of $157,258 per employee. Receivables Turnover for the company is 4.57 with a Total Asset Turnover recorded at a value of 0.34.Alexion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.00 and a Current Ratio set at 4.50.
Alexion Pharmaceuticals Inc. [ALXN]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ALXN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Alexion Pharmaceuticals Inc. go to 8.49%.
An analysis of insider ownership at Alexion Pharmaceuticals Inc. [ALXN]
There are presently around $34,808 million, or 87.70% of ALXN stock, in the hands of institutional investors. The top three institutional holders of ALXN stocks are: VANGUARD GROUP INC with ownership of 19,568,983, which is approximately 0.836% of the company’s market cap and around 0.40% of the total institutional ownership; BLACKROCK INC., holding 17,550,295 shares of the stock with an approximate value of $3.23 billion in ALXN stocks shares; and STATE STREET CORP, currently with $1.82 billion in ALXN stock with ownership of nearly -7.069% of the company’s market capitalization.
Positions in Alexion Pharmaceuticals Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 317 institutional holders increased their position in Alexion Pharmaceuticals Inc. [NASDAQ:ALXN] by around 42,191,568 shares. Additionally, 462 investors decreased positions by around 46,757,951 shares, while 107 investors held positions by with 100,016,608 shares. The mentioned changes placed institutional holdings at 188,966,127 shares, according to the latest SEC report filing. ALXN stock had 81 new institutional investments in for a total of 8,716,299 shares, while 146 institutional investors sold positions of 12,000,361 shares during the same period.